Gene · 1237
Papers2,300
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
181 to 200 of 2,300
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Pan-Cancer Analysis and Experimental Validation of SOX4 as a Potential Diagnosis, Prognosis, and Immunotherapy Biomarker. | Cancers (Basel) | 2023 | 37958409 | PubTator, text mining | PubMed |
| Comparative immunological landscape between pre- and early-stage LUAD manifested as ground-glass nodules revealed by scRNA and scTCR integrated analysis. | Cell Commun Signal | 2023 | 37957625 | PubTator, text mining | PubMed |
| Quercetin as a possible complementary therapy in multiple sclerosis: Anti-oxidative, anti-inflammatory and remyelination potential properties. | Heliyon | 2023 | 37954351 | PubTator, text mining | PubMed |
| CD4+CCR8+ Tregs in ovarian cancer: a potential effector Tregs for immune regulation. | J Transl Med | 2023 | 37950246 | PubTator, text mining | PubMed |
| Transcriptomic analysis reveals that RasGEF1b deletion alters basal and LPS-induced expression of genes involved in chemotaxis and cytokine responses in macrophages. | Sci Rep | 2023 | 37950057 | PubTator, text mining | PubMed |
| Targeting post-translational modifications of Foxp3: a new paradigm for regulatory T cell-specific therapy. | Front Immunol | 2023 | 37936703 | PubTator, text mining | PubMed |
| Mutant p53R211* ameliorates inflammatory arthritis in AIA rats via inhibition of TBK1-IRF3 innate immune response. | Inflamm Res | 2023 | 37935918 | PubTator, text mining | PubMed |
| Selective reprogramming of regulatory T cells in solid tumors can strongly enhance or inhibit tumor growth. | Front Immunol | 2023 | 37928524 | PubTator, text mining | PubMed |
| Adjusting the dose of traditional drugs combined with immunotherapy: reshaping the immune microenvironment in lung cancer. | Front Immunol | 2023 | 37901223 | PubTator, text mining | PubMed |
| Unlocking the potential of Tregs: innovations in CAR technology. | Front Mol Biosci | 2023 | 37900916 | PubTator, text mining | PubMed |
| HLA-DPA1 overexpression inhibits cancer progression, reduces resistance to cisplatin, and correlates with increased immune infiltration in lung adenocarcinoma. | Aging (Albany NY) | 2023 | 37899135 | PubTator, text mining | PubMed |
| Precision and Safety of Ultrasound-Guided versus Palpation-Guided Needle Placement on the Patellar Tendon: A Cadaveric Study. | Life (Basel) | 2023 | 37895441 | PubTator, text mining | PubMed |
| CD39+ conventional CD4+ T cells with exhaustion traits and cytotoxic potential infiltrate tumors and expand upon CTLA-4 blockade. | Oncoimmunology | 2023 | 37885970 | PubTator, text mining | PubMed |
| Immunological role and clinical prognostic significance of P2RY6 in lung adenocarcinoma: a multi-omics studies and single-cell sequencing analysis. | World J Surg Oncol | 2023 | 37880703 | PubTator, text mining | PubMed |
| Regulatory T cells in skin regeneration and wound healing. | Mil Med Res | 2023 | 37867188 | PubTator, text mining | PubMed |
| Identification and validation of PCSK9 as a prognostic and immune-related influencing factor in tumorigenesis: a pan-cancer analysis. | Front Oncol | 2023 | 37860186 | PubTator, text mining | PubMed |
| Overexpression of SH2D1A promotes cancer progression and is associated with immune cell infiltration in hepatocellular carcinoma via bioinformatics and in vitro study. | BMC Cancer | 2023 | 37858067 | PubTator, text mining | PubMed |
| CRISPR-Cas9 delivery strategies with engineered extracellular vesicles. | Mol Ther Nucleic Acids | 2023 | 37842166 | PubTator, text mining | PubMed |
| Expression of CKS2 in Hepatocellular Carcinoma: Correlation with Survival Outcomes and Immune Microenvironment. | J Hepatocell Carcinoma | 2023 | 37841370 | PubTator, text mining | PubMed |
| Dual Functions of T Lymphocytes in Breast Carcinoma: From Immune Protection to Orchestrating Tumor Progression and Metastasis. | Cancers (Basel) | 2023 | 37835465 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1237/papers?page=10